IMV

IMV EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of IMV (IMVIF) as of Oct 25, 2026 is -0.01. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -0.01 — a change of 4.03% (lower).

EV/EBIT

-0.01

YoY

4.03%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of IMV is 2022 -0.01 . EV/EBIT (Enterprise Value to EBIT) of IMV was 2021 -0.01 . It decreases by 4.03% lower compared to the previous year.

The IMV EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EV/EBIT
Date
EV/EBIT
Jan 1, 2018
-0.01 USD
Jan 1, 2019
-0.01 USD
Jan 1, 2020
-0.01 USD
Jan 1, 2021
-0.01 USD
Jan 1, 2022
-0.01 USD
Jan 1, 2023 (e)
0.00 USD
Jan 1, 2024 (e)
0.00 USD
Jan 1, 2025 (e)
0.00 USD
The IMV EV/EBIT history
YEAREV/EBITYoY
est0.00—
est0.00—
est0.00-100.00%
-0.01+4.03%
-0.01-12.31%
-0.01-36.65%
-0.01-31.18%
-0.01-18.62%
-0.02-33.97%
-0.03+6.35%
-0.03-16.83%
-0.03—
0.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

IMV Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides IMV's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates IMV's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots IMV's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if IMV grows earnings faster than its peers.

IMV Stock analysis

What does IMV do? IMV, Inc. develops novel cancer immunotherapies and vaccines, focusing on DPX-based cancer vaccines like maveropepimut-S (MVP-S). MVP-S targets survivin, a cancer antigen overexpressed in advanced cancers, and includes an innate immune activator and CD4 T cell helper peptide. It is administered every two months in low doses, driving persistent immune attacks on tumor cells. The company evaluates MVP-S in Phase IIB trials for advanced r/r Diffuse Large B Cell Lymphoma and platinum resistant ovarian cancer. IMV, Inc. generates revenue through clinical development and potential future commercialization of its DPX platform-based therapies. The primary therapeutic candidate, MVP-S, is being tested in Phase IIB trials for specific cancer types, with the company aiming to secure regulatory approvals for these indications. The firm's focus on DPX technology positions it to develop additional cancer vaccines targeting various antigens. The company's target segments include patients with advanced solid or hematological cancers, particularly those with r/r Diffuse Large B Cell Lymphoma and platinum resistant ovarian cancer. These patient groups represent high unmet medical needs, aligning with IMV's focus on developing therapies for difficult-to-treat cancers. IMV's business model relies on advancing clinical trials to demonstrate efficacy and safety, paving the way for potential partnerships or direct sales once approved. IMV is one of the most popular companies on Eulerpool.

Frequently Asked Questions about IMV stock

EV/EBIT (Enterprise Value to EBIT) of IMV is -0.01 in 2022.

EV/EBIT (Enterprise Value to EBIT) of IMV changed from -0.01 to -0.01, representing a 4.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) IMV since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s IMV with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Valuation — IMV

All Key Metrics — IMV